The global market size was valued at US$ 1.34 billion in 2024 and is projected to reach US$ 2.15 billion by 2030, at a CAGR of 8.2% during the forecast period 2024-2030.
The United States market size was valued at US$ 445.6 million in 2024 and is projected to reach US$ 687.3 million by 2030, at a CAGR of 7.5% during the forecast period 2024-2030.
Pharmaceutical treatments targeting primary biliary cholangitis, an autoimmune liver disease.
The market shows strong growth, driven by novel therapies. In 2023, patient population reached 245,000 in developed markets. Novel treatments grow at 9.2% annually. Market saw 42% increase in clinical trials in 2023. Regulatory frameworks updated in 45 countries. Future investments of US$ 645.8 million planned in R&D by 2026. North America leads with 43% market share.
Report Overview
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.
This report provides a deep insight into the global Primary Biliary Cholangitis Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Primary Biliary Cholangitis Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Primary Biliary Cholangitis Therapeutics market in any manner.
Global Primary Biliary Cholangitis Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Abbott Laboratories
Allergan Plc
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Takeda Pharmaceutical Co. Ltd.
Market Segmentation (by Type)
OCALIVA
Ursodiol
Others
Market Segmentation (by Application)
Hospital
Private Clinic
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Primary Biliary Cholangitis Therapeutics Market
Overview of the regional outlook of the Primary Biliary Cholangitis Therapeutics Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Primary Biliary Cholangitis Therapeutics
1.2 Key Market Segments
1.2.1 Primary Biliary Cholangitis Therapeutics Segment by Type
1.2.2 Primary Biliary Cholangitis Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Primary Biliary Cholangitis Therapeutics Market Overview
2.1 Global Market Overview
2.1.1 Global Primary Biliary Cholangitis Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Primary Biliary Cholangitis Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Primary Biliary Cholangitis Therapeutics Market Competitive Landscape
3.1 Global Primary Biliary Cholangitis Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Primary Biliary Cholangitis Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Primary Biliary Cholangitis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Primary Biliary Cholangitis Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Primary Biliary Cholangitis Therapeutics Sales Sites, Area Served, Product Type
3.6 Primary Biliary Cholangitis Therapeutics Market Competitive Situation and Trends
3.6.1 Primary Biliary Cholangitis Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Primary Biliary Cholangitis Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Primary Biliary Cholangitis Therapeutics Industry Chain Analysis
4.1 Primary Biliary Cholangitis Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Primary Biliary Cholangitis Therapeutics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Primary Biliary Cholangitis Therapeutics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Primary Biliary Cholangitis Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Primary Biliary Cholangitis Therapeutics Price by Type (2019-2024)
7 Primary Biliary Cholangitis Therapeutics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Primary Biliary Cholangitis Therapeutics Market Sales by Application (2019-2024)
7.3 Global Primary Biliary Cholangitis Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Primary Biliary Cholangitis Therapeutics Sales Growth Rate by Application (2019-2024)
8 Primary Biliary Cholangitis Therapeutics Market Segmentation by Region
8.1 Global Primary Biliary Cholangitis Therapeutics Sales by Region
8.1.1 Global Primary Biliary Cholangitis Therapeutics Sales by Region
8.1.2 Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Primary Biliary Cholangitis Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Primary Biliary Cholangitis Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Primary Biliary Cholangitis Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Primary Biliary Cholangitis Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Primary Biliary Cholangitis Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Abbott Laboratories
9.1.1 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Basic Information
9.1.2 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product Overview
9.1.3 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product Market Performance
9.1.4 Abbott Laboratories Business Overview
9.1.5 Abbott Laboratories Primary Biliary Cholangitis Therapeutics SWOT Analysis
9.1.6 Abbott Laboratories Recent Developments
9.2 Allergan Plc
9.2.1 Allergan Plc Primary Biliary Cholangitis Therapeutics Basic Information
9.2.2 Allergan Plc Primary Biliary Cholangitis Therapeutics Product Overview
9.2.3 Allergan Plc Primary Biliary Cholangitis Therapeutics Product Market Performance
9.2.4 Allergan Plc Business Overview
9.2.5 Allergan Plc Primary Biliary Cholangitis Therapeutics SWOT Analysis
9.2.6 Allergan Plc Recent Developments
9.3 Eli Lilly and Co.
9.3.1 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Basic Information
9.3.2 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product Overview
9.3.3 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product Market Performance
9.3.4 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics SWOT Analysis
9.3.5 Eli Lilly and Co. Business Overview
9.3.6 Eli Lilly and Co. Recent Developments
9.4 Intercept Pharmaceuticals Inc.
9.4.1 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Basic Information
9.4.2 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product Overview
9.4.3 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product Market Performance
9.4.4 Intercept Pharmaceuticals Inc. Business Overview
9.4.5 Intercept Pharmaceuticals Inc. Recent Developments
9.5 Takeda Pharmaceutical Co. Ltd.
9.5.1 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Basic Information
9.5.2 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Product Overview
9.5.3 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Product Market Performance
9.5.4 Takeda Pharmaceutical Co. Ltd. Business Overview
9.5.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
10 Primary Biliary Cholangitis Therapeutics Market Forecast by Region
10.1 Global Primary Biliary Cholangitis Therapeutics Market Size Forecast
10.2 Global Primary Biliary Cholangitis Therapeutics Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Primary Biliary Cholangitis Therapeutics Market Size Forecast by Country
10.2.3 Asia Pacific Primary Biliary Cholangitis Therapeutics Market Size Forecast by Region
10.2.4 South America Primary Biliary Cholangitis Therapeutics Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Primary Biliary Cholangitis Therapeutics by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Primary Biliary Cholangitis Therapeutics Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Primary Biliary Cholangitis Therapeutics by Type (2025-2030)
11.1.2 Global Primary Biliary Cholangitis Therapeutics Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Primary Biliary Cholangitis Therapeutics by Type (2025-2030)
11.2 Global Primary Biliary Cholangitis Therapeutics Market Forecast by Application (2025-2030)
11.2.1 Global Primary Biliary Cholangitis Therapeutics Sales (K Units) Forecast by Application
11.2.2 Global Primary Biliary Cholangitis Therapeutics Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Primary Biliary Cholangitis Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Primary Biliary Cholangitis Therapeutics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Primary Biliary Cholangitis Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Primary Biliary Cholangitis Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Biliary Cholangitis Therapeutics as of 2022)
Table 10. Global Market Primary Biliary Cholangitis Therapeutics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Primary Biliary Cholangitis Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Primary Biliary Cholangitis Therapeutics Product Type
Table 13. Global Primary Biliary Cholangitis Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Primary Biliary Cholangitis Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Primary Biliary Cholangitis Therapeutics Market Challenges
Table 22. Global Primary Biliary Cholangitis Therapeutics Sales by Type (K Units)
Table 23. Global Primary Biliary Cholangitis Therapeutics Market Size by Type (M USD)
Table 24. Global Primary Biliary Cholangitis Therapeutics Sales (K Units) by Type (2019-2024)
Table 25. Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Primary Biliary Cholangitis Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Primary Biliary Cholangitis Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Primary Biliary Cholangitis Therapeutics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Primary Biliary Cholangitis Therapeutics Sales (K Units) by Application
Table 30. Global Primary Biliary Cholangitis Therapeutics Market Size by Application
Table 31. Global Primary Biliary Cholangitis Therapeutics Sales by Application (2019-2024) & (K Units)
Table 32. Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Primary Biliary Cholangitis Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2024)
Table 35. Global Primary Biliary Cholangitis Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Primary Biliary Cholangitis Therapeutics Sales by Region (2019-2024) & (K Units)
Table 37. Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Primary Biliary Cholangitis Therapeutics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Primary Biliary Cholangitis Therapeutics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Primary Biliary Cholangitis Therapeutics Sales by Region (2019-2024) & (K Units)
Table 41. South America Primary Biliary Cholangitis Therapeutics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Primary Biliary Cholangitis Therapeutics Sales by Region (2019-2024) & (K Units)
Table 43. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Basic Information
Table 44. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product Overview
Table 45. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Abbott Laboratories Business Overview
Table 47. Abbott Laboratories Primary Biliary Cholangitis Therapeutics SWOT Analysis
Table 48. Abbott Laboratories Recent Developments
Table 49. Allergan Plc Primary Biliary Cholangitis Therapeutics Basic Information
Table 50. Allergan Plc Primary Biliary Cholangitis Therapeutics Product Overview
Table 51. Allergan Plc Primary Biliary Cholangitis Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Allergan Plc Business Overview
Table 53. Allergan Plc Primary Biliary Cholangitis Therapeutics SWOT Analysis
Table 54. Allergan Plc Recent Developments
Table 55. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Basic Information
Table 56. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product Overview
Table 57. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics SWOT Analysis
Table 59. Eli Lilly and Co. Business Overview
Table 60. Eli Lilly and Co. Recent Developments
Table 61. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Basic Information
Table 62. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product Overview
Table 63. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Intercept Pharmaceuticals Inc. Business Overview
Table 65. Intercept Pharmaceuticals Inc. Recent Developments
Table 66. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Basic Information
Table 67. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Product Overview
Table 68. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Takeda Pharmaceutical Co. Ltd. Business Overview
Table 70. Takeda Pharmaceutical Co. Ltd. Recent Developments
Table 71. Global Primary Biliary Cholangitis Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 72. Global Primary Biliary Cholangitis Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 73. North America Primary Biliary Cholangitis Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 74. North America Primary Biliary Cholangitis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 75. Europe Primary Biliary Cholangitis Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 76. Europe Primary Biliary Cholangitis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 77. Asia Pacific Primary Biliary Cholangitis Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 78. Asia Pacific Primary Biliary Cholangitis Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 79. South America Primary Biliary Cholangitis Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 80. South America Primary Biliary Cholangitis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 81. Middle East and Africa Primary Biliary Cholangitis Therapeutics Consumption Forecast by Country (2025-2030) & (Units)
Table 82. Middle East and Africa Primary Biliary Cholangitis Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 83. Global Primary Biliary Cholangitis Therapeutics Sales Forecast by Type (2025-2030) & (K Units)
Table 84. Global Primary Biliary Cholangitis Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)
Table 85. Global Primary Biliary Cholangitis Therapeutics Price Forecast by Type (2025-2030) & (USD/Unit)
Table 86. Global Primary Biliary Cholangitis Therapeutics Sales (K Units) Forecast by Application (2025-2030)
Table 87. Global Primary Biliary Cholangitis Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Primary Biliary Cholangitis Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Primary Biliary Cholangitis Therapeutics Market Size (M USD), 2019-2030
Figure 5. Global Primary Biliary Cholangitis Therapeutics Market Size (M USD) (2019-2030)
Figure 6. Global Primary Biliary Cholangitis Therapeutics Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Primary Biliary Cholangitis Therapeutics Market Size by Country (M USD)
Figure 11. Primary Biliary Cholangitis Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Primary Biliary Cholangitis Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Primary Biliary Cholangitis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Primary Biliary Cholangitis Therapeutics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Primary Biliary Cholangitis Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Primary Biliary Cholangitis Therapeutics Market Share by Type
Figure 18. Sales Market Share of Primary Biliary Cholangitis Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Primary Biliary Cholangitis Therapeutics by Type in 2023
Figure 20. Market Size Share of Primary Biliary Cholangitis Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Primary Biliary Cholangitis Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Primary Biliary Cholangitis Therapeutics Market Share by Application
Figure 24. Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Primary Biliary Cholangitis Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Primary Biliary Cholangitis Therapeutics Market Share by Application in 2023
Figure 28. Global Primary Biliary Cholangitis Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Primary Biliary Cholangitis Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Primary Biliary Cholangitis Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Primary Biliary Cholangitis Therapeutics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Primary Biliary Cholangitis Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Primary Biliary Cholangitis Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Primary Biliary Cholangitis Therapeutics Sales Market Share by Region in 2023
Figure 44. China Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (K Units)
Figure 50. South America Primary Biliary Cholangitis Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Primary Biliary Cholangitis Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Primary Biliary Cholangitis Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Primary Biliary Cholangitis Therapeutics Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Primary Biliary Cholangitis Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Primary Biliary Cholangitis Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Primary Biliary Cholangitis Therapeutics Market Share Forecast by Type (2025-2030)
Figure 65. Global Primary Biliary Cholangitis Therapeutics Sales Forecast by Application (2025-2030)
Figure 66. Global Primary Biliary Cholangitis Therapeutics Market Share Forecast by Application (2025-2030)
